ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XENE / earnings
AMLX (39) OGN (70) IRON (54) ACAD (49) ⌘ Pro Terminal →

Xenon Pharmaceuticals Inc. (XENE) Next Earnings Date & Expected ±6.9% Move

$37.62 +0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $37.59

Xenon Pharmaceuticals Inc. (XENE) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.62B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XENE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XENE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $37.62 (+0.56% 1D, market cap $3.62B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XENE ranks #527 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XENE compare to AMLX and OGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XENE carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XENE?
▼

Per XENE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001582313), Xenon Pharmaceuticals Inc. generated $1.04B in revenue (+33.6% YoY), -$345.9M in net income, and -$279.9M in free cash flow against $633.2M in total assets and $23.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $37.59 (-0.09%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (4)SEC (14)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$76 Bull$34 Base$27 Bear
📬 FREE XENE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XENE)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY XENE SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (38% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$33.90+6% Next Q
Q2 (-2Q)
32
Grade E$35.95+1.1% Next Q
Q3 (-1Q)
34
Grade E$36.34+3.5% Next Q
Current
37
Grade D-$37.62-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XENE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XENE currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($43.96) and Max Pain ($39.50) forces dealer call-delta covering toward $76.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XENE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XENE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±6.9% Swing Band

±$2.60 Expected Swing
$35.02 (-6.9%)Spot $37.62$40.22 (+6.9%)
MODEL EARNINGS SETUP GAUGE

XENE Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $-3.57 • YoY Revenue Growth: 7.7%

Model Bullish Setup (37/100)Model Risk Weight (63/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$1.04B-$345.9M-$279.9M52%
FY 20242024-12-31$782.0M-$234.3M-$184.5M52%
FY 20232023-12-31$599.4M-$182.4M-$151.1M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XENE)

  • ✓Walkthrough of XENE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XENE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.46%⚡ TESTING RESISTANCE
2026-11-03O $37.54H $37.62L $37.41C $37.62VOL 1.12M
RES: $37.61SUP: $30.54SMA50: $43.96SMA200: $52.32
$75.41$64.02$52.63$41.24$29.84RES $37.61SUP $30.54$37.622026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XENE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XENE Butterfly Map → + Track XENE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
22.3%/yr Implied 5Y Growth

vs. +33.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XENE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XENE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XENE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XENE)

Health Care Rank #527 of 1015 ⚔️ AMLX vs XENE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XENE vs. AMLX, OGN, IRON, ACAD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Xenon Pharmaceuticals Inc. (XENE) ranks #527 by composite RQD confidence (37/100, grade D-) and #189 by equity capitalization ($3.62B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with XENE at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XENE ACTIVE
Xenon Pharmaceuticals Inc.
D- 37/100 — — -35.0% +0.56% $3.62B Benchmark Subject
AMLX
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.84% $3.62B /amlx-vs-xene →
OGN
Organon & Co.
B- 70/100 19.4x 53.3% 24.9% -0.14% $3.63B /ogn-vs-xene →
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.75% $3.59B /iron-vs-xene →
ACAD
ACADIA Pharmaceuticals Inc.
D 49/100 9.1x 91.7% 7.9% -0.58% $3.55B /acad-vs-xene →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001582313 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xenon Pharmaceuticals Inc. (XENE) reported GAAP revenue of $1.04B (+33.6% vs. FY2024 revenue of $782.0M , and +74.3% cumulative change since FY2023) , GAAP net income of -$345.9M, operating cash flow of -$279.1M, and free cash flow of -$279.9M (-51.7% YoY). On the balance sheet, XENE closed FY2025 with $633.2M in total assets against $23.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.04B -$345.9M -$279.1M -$279.9M $633.2M $23.1M
FY2024 (FY) 2024-12-31 $782.0M -$234.3M -$181.4M -$184.5M $798.1M $19.5M
FY2023 (FY) 2023-12-31 $599.4M -$182.4M -$151.1M -$151.1M $2.00B $467.9M

3. XENE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XENE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $37.62 (+0.56% 1D, market cap $3.62B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XENE ranks #527 in composite RQD confidence.

How does XENE compare to AMLX and OGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XENE carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XENE?

Per XENE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001582313), Xenon Pharmaceuticals Inc. generated $1.04B in revenue (+33.6% YoY), -$345.9M in net income, and -$279.9M in free cash flow against $633.2M in total assets and $23.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XENE trading relative to its 50-day, 200-day, and 52-week technical levels?

XENE last traded at $37.62 (+0.56% on volume of 2,380,717 shares), positioning the stock -14.42% below its 50-day simple moving average ($43.96) and -28.10% below its 200-day simple moving average ($52.32). Across its 52-week range of $33.38 to $72.66, XENE sits at the 10.8% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($35.02 to $40.22).

Direct Sub-Reports: XENE RQD Cockpit XENE 12M Forecast XENE Earnings & Move XENE Dividends & DRIP XENE Insiders & 13F XENE Whale Options XENE Profit Sankey XENE News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

XENE — Xenon Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Xenon Pharmaceuticals Inc. (XENE) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $37.62 (+0.56% 1D, market capitalization $3.62B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -36.7%, and free cash flow yield of -7.70%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (14/20): Incorporates a 1.10x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.04x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Xenon Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $3.6B. Reported revenue for FY 2025 is —, so the company does not currently generate revenue in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xenon Pharmaceuticals Inc. (XENE) reported $1.04B in annual revenue (up from $782.0M in FY2024, +33.6% YoY) and -$345.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($599.4M revenue, -$182.4M net income) through FY2025, XENE scaled operating cash flow to -$279.1M and free cash flow to -$279.9M, backed by $633.2M in total assets against $23.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.70% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $33.38 – $72.66 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -36.7% operating margins and a 1.10x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should note that the absence of recorded links is a data gap, not evidence of independence.

  • Key Question #1: Can XENE sustain or expand its -36.7% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.04B and free cash flow of -$279.9M, how will capital allocation balance growth reinvestment against $23.1M in total debt?
  • Key Question #3: How sensitive is XENE's 29.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.10x)?

XENE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xenon Pharmaceuticals Inc. (XENE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XENE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XENE Bull vs. Bear Conversation Board — What's Your Call at $37.62?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XENE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XENE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $45.64 (+22.0%)
📌 Pinned Debate

The forensic balance sheet is strong, with Debt/Equity of 0.04, Altman Z of 26, and cash rising to $199.2M while debt fell to $23.1M.

Picked up a starter position in XENE in my $100K Virtual Cash book at $37.41. The forensic balance sheet is strong, with Debt/Equity of 0.04, Altman Z of 26, and cash rising to $199.2M while debt fell to $23.1M.. Trading inside a $33.38–$72.66 52-week range with -7.7% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — XENE's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $28.81 (-23.0%)
Spot @ $37.41

Cash burn is accelerating, with FY 2025 FCF of -$279.9M against $0.0M revenue and ROIC of -35%.

Cash burn is accelerating, with FY 2025 FCF of -$279.9M against $0.0M revenue and ROIC of -35%.. Look at the math on XENE: paying 29.0x forward P/E for -35.0% ROIC and -36.7% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $32.92 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%